戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 seline susceptibility to the antibiotic para-aminosalicylic acid.
2 nce of remission of mild to moderate UC is 5-aminosalicylic acid.
3 tment with infliximab (0.36; P = .0005) or 5-aminosalicylic acid (0.44; P < .0001) were associated wi
4                                        The 5-aminosalicylic acid (5-ASA) agents and oral steroids rem
5 e group treated with the anti-inflammatory 5-aminosalicylic acid (5-ASA) and one group untreated), wi
6 al oxygenation, but the PPAR-gamma agonist 5-aminosalicylic acid (5-ASA) functionally replaced Clostr
7 used inflammatory bowel disease (IBD) drug 5-aminosalicylic acid (5-ASA) has been attributed, in part
8                  We recently reported that 5-aminosalicylic acid (5-ASA) inhibits TNFalpha-regulated
9 able for inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) is still the key medication,
10 L-1-mediated COX-2 gene expression whereas 5-aminosalicylic acid (5-ASA) or indomethacin had no effec
11 AIDs) 4-aminophenylacetic acid (4-APAA) or 5-aminosalicylic acid (5-ASA) with peptides, including an
12 nd its metabolites, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA), on components of angiogenes
13  two strategies for delivering mesalazine (5-aminosalicylic acid, 5-ASA) to the colon were compared i
14 rences in the in vitro response of PPK1 to 5-aminosalicylic acid, a known PPK1 inhibitor, and observe
15 ory drugs (OR, 0.1; 95% CI: 0.03-0.5), and 5-aminosalicylic acid agents (OR, 0.4; 95% CI: 0.2-0.9), a
16 Cs for three antibiotics (pyrazinamide, para-aminosalicylic acid, and isoniazid) recapitulates known
17 sulfasalazine (SSZ) with its two moieties, 5-aminosalicylic acid (ASA) and sulfapyridine (SP), in pat
18 , and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate).
19 , ofloxacin, moxifloxacin, ethionamide, para-aminosalicylic acid, cycloserine, and linezolid.
20                           Corticosteroids, 5-aminosalicylic acid derivatives, immunomodulators, and m
21  Treatments for inducing remission include 5-aminosalicylic acid drugs and corticosteroids.
22  Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressa
23             Maintenance treatments include 5-aminosalicylic acid drugs, thiopurines, biologics (eg, a
24           Two lanthanide complexes, namely 5-aminosalicylic acid ethylenediaminetetraacetate europium
25 aacetate europium(III) (5As-EDTA-Eu3+) and 4-aminosalicylic acid ethylenediaminetetraacetate terbium(
26 al data to predict the release of the drug 5-aminosalicylic acid from polysaccharide-based coatings i
27                        Streptomycin and para-aminosalicylic acid had just been discovered; the discov
28 nventional therapy, once daily therapy for 5-aminosalicylic acid is generally sufficient.
29 , ofloxacin, moxifloxacin, ethionamide, para-aminosalicylic acid, linezolid, and cycloserine and comp
30                         Furthermore, a new 5-aminosalicylic acid (mesalamine MMX) has been released t
31                             Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay in
32 eatment with a regimen based on capreomycin, aminosalicylic acid, or both).
33 quency of dosing for standard 4-g doses of p-aminosalicylic acid (PAS) granules.
34                                         para-Aminosalicylic acid (PAS) is one of the antimycobacteria
35 ti-infective target, and the antifolate para-aminosalicylic acid (PAS) was one of the first anti-infe
36  synthase (DHPS), such as sulfonamides and p-aminosalicylic acid (PAS), we hypothesized that bacteria
37  use of second-line antibiotics such as para-aminosalicylic acid (PAS).
38 ification; and use of sulfasalazine, other 5-aminosalicylic acid preparations, prednisone, cyclospori
39               Surveillance colonoscopy and 5-aminosalicylic acid therapy may mitigate cancer risk, bu
40 tective factors colonoscopic surveillance, 5-Aminosalicylic Acid, thiopurines, and smoking was modera
41 wed by acylation with N-hydroxysuccinimide p-aminosalicylic acid to form the final product, i.e., 5-[
42 ctive treatment for mild to moderate UC is 5-aminosalicylic acid, whereas moderate to severe UC can b
43 sensitization of Eu3+ is accomplished with 5-aminosalicylic acid, which provides energy transfer for